Neogen Corporation (NEOG) - Stock Analysis
Last updated: Jun 13, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Neogen shows improving operational execution with a stable revenue base, cost savings initiatives, and positive industry tailwinds. The stock exhibits positive technical momentum and analyst upgrades. Legal headwinds remain but ongoing margin expansion and upcoming earnings confer cautious near-term upside potential.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Cash Flow ⢠Liquidity Cushion ⢠Intangible Risk NEOG showed a meaningful quarterly improvement with positive EBITDA and free cash flow plus strong liquidity, but it remains loss-making, levered, and dependent on intangible assets.
Price Behavior
Key Price Behavior Insights: ⢠Higher lows ⢠Stalled resistance ⢠Volatile pullbacks Support Level: $8.35-$8.75 Resistance Level: $9.25-$9.30 NEOG has drifted higher over the last month with higher lows and support near $8.35-$8.75, but repeated rejection around $9.25-$9.30 keeps the recovery cautious until a clear breakout above $9.30.
AI Summary
NEOG now looks like a genuine turnaround rather than a simple recovery, with both segments back to core growth, EBITDA margin expanding to 21.7%, and free cash flow positive, but the stock still hinges on whether management can sustain these gains amid weak end markets and convert cost cuts/divestitures into durable profitability.
Description
Neogen Corporation develops, manufactures and sells products used to detect, mitigate and monitor biological, chemical and sanitary hazards across the food and animal sectors. Its Food Safety business supplies diagnostic test kits and sanitation assays to food and feed producers, processors, grain handlers, dairies, laboratories and related manufacturers to identify pathogens, toxins, residues, allergens and other contaminants, while its Animal Safety business provides veterinary medicines, vaccines, diagnostic tools, disinfectants and genomics services, including drug-residue and toxicology testing for animals. The company was incorporated in 1981 and is headquartered in Lansing, Michigan.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 1 | Jan 8 | NEOG | Neogen Corporation | Neogen shows improving operational execution with a stable revenue base, cost savings initiatives, and positive industry tailwinds. The stock exhibits positive technical momentum and analyst upgrades. Legal headwinds remain but ongoing margin expansion and upcoming earnings confer cautious near-term upside potential. | Closed | +38.9% |